Filing Flows › Organogenesis Holdings (ORGO) › Q3 2026
Organogenesis Holdings (ORGO) Q3 2026 earnings results (third quarter 2026)
10-Q filed Nov 5, 2026
Organogenesis Holdings (ORGO) reported revenue of $45.5M for the third quarter 2026 (Q3 2026), -70% from a year earlier and +4% from the quarter before. Operating margin was -64.9%, net loss $29.6M (65.2% of revenue).
Organogenesis Holdings, Q3 2026: revenue $45.5M (-70% year over year), operating margin -64.9%, net loss $29.6M, operating cash flow −$18.6M. The chart follows the revenue to costs, profit and cash.
| Q3 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $45.5M | +4% | -70% |
| Operating profit | −$29.5M | — | -242% |
| Net earnings | −$29.6M | — | -237% |
| Operating cash flow | −$18.6M | — | -704% |
What changed
Revenue was $45.5M in Q3 2026, down 70% year over year and up 4% from the previous quarter.
Operating costs exceeded revenue by $29.5M, an operating margin of -64.9%. Total costs fell 42% while revenue fell 70%. The quarter ended with a net loss of $29.6M, narrower than the previous quarter's $96.3M loss.
Operating cash flow was −$18.6M. Non-cash charges added back $3.9M of depreciation and amortization and $2.8M of share-based compensation. Working capital and other items added $4.3M. Capital expenditures of $1.5M exceeded it, leaving free cash flow of −$20.1M.
Questions
What was Organogenesis Holdings' revenue in the third quarter 2026?
Organogenesis Holdings (ORGO) reported revenue of $45.5M for the third quarter 2026 (Q3 2026), -70% from a year earlier and +4% from the quarter before.
Was Organogenesis Holdings profitable in the third quarter 2026?
Operating loss was $29.5M (-64.9% of revenue) and net loss $29.6M.